End­points 11 win­ner As­cid­i­an Ther­a­peu­tics: A search-and-re­place tech­nol­o­gy comes to RNA ...

The FDA has approved Johnson & Johnson’s IL-23 blocker Tremfya to treat ulcerative colitis, a boost to the pharma’s hopes that the drug will serve as a worthy follow-up to ...

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Teladoc Health's CEO Jason Gorevic is stepping down ...

Below are notable updates from the American Academy of Dermatology’s annual meeting over the weekend: Sanofi amends trial protocol Sanofi has big plans for amlitelimab, the monoclonal antibody ...

Reps. Kelly Armstrong (R-ND) and Ben Cline (R-VA) sent a letter last week to Attorney General Merrick Garland, asking why the Department of Justice is willing to incur potential patent ...

Merck has struck a deal to buy Harpoon Therapeutics for $680 million, beefing up its oncology pipeline with a portfolio of T cell engagers. At $23 per share, Merck’s offer ...

As Eli Lilly launches its newly approved weight loss med Zepbound to much fanfare, Novo Nordisk is tossing a next-gen candidate in the ring. The Danish pharma company is launching ...

After years of being a rumored biotech buyout target, Mirati was ultimately acquired by Bristol Myers Squibb earlier this month for $4.8 billion. But the pharma buyer once offered more ...

When actor Bellamy Young was growing up, her father suffered from a brain disorder called hepatic encephalopathy (HE) caused by cirrhosis of the liver. She knows the stigma and isolation ...

Sage Therapeutics is laying off 40% of its workforce this quarter in the wake of the FDA's rejection of the biotech’s major depressive disorder drug earlier ...

The impact of Novo Nordisk’s GLP-1 semaglutide on cardiovascular health was received with great fanfare earlier this month, with the Danish pharma touting a 20% reduction in major adverse ...

Medical advocacy group Médecins Sans Frontières (MSF), also known as Doctors Without Borders, called upon ViiV Healthcare Thursday to cut a confidentiality clause and revise supply ...